Business Context and Reporting Period
This Form 8-K filing by Outlook Therapeutics, Inc. (OTLK) reports a significant executive leadership transition. The report date is August 23, 2026, with the effective transition date for the new Chief Financial Officer (CFO) set for September 1, 2026.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
- Departure of CFO: Lawrence A. Kenyon ceased serving as CFO, Treasurer, Corporate Secretary, and Board member effective September 1, 2026. He will remain in a non-executive role until September 30, 2026.
- Appointment of New CFO: Kevin Lundquist was appointed as CFO, Treasurer, principal financial officer, and principal accounting officer effective September 1, 2026.
- Board Composition: The Board size will be reduced to eight directors immediately upon Mr. Kenyon's departure.
Compensation, Outlook, and Risks
New CFO Compensation (Kevin Lundquist)
- Base Salary: $450,000 annually.
- Bonus: Target annual performance-based cash bonus of 50% of base salary.
- Equity Grant: 500,000 stock options (outside the 2024 Equity Incentive Plan) with a 10-year term. Vesting schedule: 25% on the first anniversary, with the remainder vesting monthly over three years.
- Severance: In the event of a "Qualifying Termination," Mr. Lundquist is entitled to nine months of base salary and up to four months of benefits. In the event of a change in control within a specific window, 100% of unvested equity accelerates.
Outgoing CFO Separation (Lawrence A. Kenyon)
- Severance Package: Includes a lump sum of 12 months of base salary, $20,000, and the full 2026 target bonus.
- Equity Acceleration: 100% acceleration of vesting for all outstanding stock options.
- Benefits: COBRA coverage for up to 12 months.
- Change in Control Provision: If a change in control occurs within two months of the separation date, severance increases to 18 months of base salary, $20,000, and 150% of the 2026 target bonus, with 18 months of COBRA.
Management Commentary: The departure is described as a mutual agreement and is not the result of any disagreement regarding accounting practices, financial statements, or internal controls.
Investor Verification Checklist
- Verify the exact vesting schedule and exercise price of the 500,000 options granted to Kevin Lundquist.
- Confirm the total cash severance liability for Lawrence A. Kenyon based on his final base salary and 2026 target bonus.
- Review the full text of the Employment Agreement (Exhibit 10.1) and Separation Agreement (Exhibit 10.2) for specific definitions of "Cause" and "Good Reason."
- Monitor the Board's plan to fill the vacancy left by Mr. Kenyon's departure from the Board.